Windlas Biotech Ltd., a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India, has announced that it has received Good Manufacturing Practices (GMP) certification for its new state-of-the-art injectable facility from the Food Safety and Drugs Administration Authority of Uttarakhand, following the inspection in December 2024.

The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.

Commenting on this development, Hitesh Windlass, Managing Director, Windlas Biotech said, “The certification marks a new chapter in Windlas Biotech’s growth trajectory, bolstering its reputation as a trusted name in the pharmaceutical manufacturing sector. This underscores our unwavering commitment to quality, innovation, and compliance with the highest regulatory standards.”

He further adds, “The GMP certification for the injectable facility not only validates our adherence to stringent manufacturing protocols but also strengthens our ability to meet the growing demand for high-quality injectable pharmaceutical products, both domestically and globally.”

The state-of-the-art facility has been designed with cutting-edge technology and advanced infrastructure to ensure the efficient and safe production of sterile injectable formulations. “Equipped with automated systems, robust quality control mechanisms, and eco-friendly processes, the facility exemplifies our strategic focus on operational excellence and sustainability,” he said.

He further added, “With this new GMP-certified injectable facility, all five of Windlas Biotech manufacturing plants are complying to this standard and we are well poised to expand our product portfolio offerings in the CDMO space. It will enable us to cater to a wider spectrum of therapeutic areas, thereby contributing to improved patient outcomes and better access to essential medicines.”